These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
456 related articles for article (PubMed ID: 31976776)
1. Comparison of inpatient admission rates of patients treated with apixaban vs. warfarin for venous thromboembolism in the emergency department. Deitelzweig S; Hlavacek P; Mardekian J; Rosenblatt L; Russ C; Tuell K; Lingohr-Smith M; Lin J; Guo JD Hosp Pract (1995); 2020 Feb; 48(1):41-48. PubMed ID: 31976776 [No Abstract] [Full Text] [Related]
2. Hospital Resource Utilization and Costs Associated With Warfarin Versus Apixaban Treatment Among Patients Hospitalized for Venous Thromboembolism in the United States. Deitelzweig S; Guo JD; Hlavacek P; Lin J; Wygant G; Rosenblatt L; Gupta A; Pan X; Mardekian J; Lingohr-Smith M; Menges B; Marshall A; Nadkarni A Clin Appl Thromb Hemost; 2018 Dec; 24(9_suppl):261S-268S. PubMed ID: 30433823 [TBL] [Abstract][Full Text] [Related]
3. Comparative Clinical and Economic Outcomes Associated with Warfarin Versus Apixaban in the Treatment of Patients with Venous Thromboembolism in a Large U.S. Commercial Claims Database. Guo JD; Rajpura J; Hlavacek P; Keshishian A; Sah J; Delinger R; Mu Q; Mardekian J; Russ C; Okano GJ; Rosenblatt L J Manag Care Spec Pharm; 2020 Aug; 26(8):1017-1026. PubMed ID: 32452277 [TBL] [Abstract][Full Text] [Related]
4. Comparison of hospital length of stay and hospitalization costs among patients with non-valvular atrial fibrillation treated with apixaban or warfarin: An early view. Xie L; Vo L; Keshishian A; Price K; Singh P; Mardekian J; Bruno A; Baser O; Kim J; Tan W; Trocio J J Med Econ; 2016 Aug; 19(8):769-76. PubMed ID: 27028360 [TBL] [Abstract][Full Text] [Related]
5. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US. Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203 [TBL] [Abstract][Full Text] [Related]
6. Safety, effectiveness, and health care cost comparisons among elderly patients with venous thromboembolism prescribed warfarin or apixaban in the United States Medicare population. Hlavacek P; Guo JD; Rosenblatt L; Keshishian A; Russ C; Mardekian J; Ferri M; Poretta T; Yuce H; McBane R Curr Med Res Opin; 2019 Dec; 35(12):2043-2051. PubMed ID: 31387467 [No Abstract] [Full Text] [Related]
7. Effectiveness and Safety of Apixaban, Low-Molecular-Weight Heparin, and Warfarin among Venous Thromboembolism Patients with Active Cancer: A U.S. Claims Data Analysis. Cohen A; Keshishian A; Lee T; Wygant G; Rosenblatt L; Hlavacek P; Mardekian J; Wiederkehr D; Sah J; Luo X Thromb Haemost; 2021 Mar; 121(3):383-395. PubMed ID: 33171521 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of direct oral factor Xa inhibitors compared with warfarin in patients with morbid obesity: a single-centre, retrospective analysis of chart data. Kushnir M; Choi Y; Eisenberg R; Rao D; Tolu S; Gao J; Mowrey W; Billett HH Lancet Haematol; 2019 Jul; 6(7):e359-e365. PubMed ID: 31133411 [TBL] [Abstract][Full Text] [Related]
9. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139 [TBL] [Abstract][Full Text] [Related]
10. Clinical and economic benefits of extended treatment with apixaban for the treatment and prevention of recurrent venous thromboembolism in Canada. Quon P; Le HH; Raymond V; Mtibaa M; Moshyk A J Med Econ; 2016 Jun; 19(6):557-67. PubMed ID: 26761644 [TBL] [Abstract][Full Text] [Related]
11. Association of Type of Oral Anticoagulant Dispensed With Adverse Clinical Outcomes in Patients Extending Anticoagulation Therapy Beyond 90 Days After Hospitalization for Venous Thromboembolism. Pawar A; Gagne JJ; Gopalakrishnan C; Iyer G; Tesfaye H; Brill G; Chin K; Bykov K JAMA; 2022 Mar; 327(11):1051-1060. PubMed ID: 35289881 [TBL] [Abstract][Full Text] [Related]
12. Effect of Apixaban Versus Warfarin Use on Health Care Resource Utilization and Costs Among Elderly Patients with Nonvalvular Atrial Fibrillation. Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J J Manag Care Spec Pharm; 2017 Nov; 23(11):1191-1201. PubMed ID: 29083968 [TBL] [Abstract][Full Text] [Related]
13. Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism. Browne C; Lanitis T; Hamilton M; Li X; Horbyluk R; Mardekian J; Kongnakorn T; Cohen A J Med Econ; 2017 Jan; 20(1):98-106. PubMed ID: 27822962 [TBL] [Abstract][Full Text] [Related]
14. Apixaban Reduces Hospitalizations in Patients With Venous Thromboembolism: An Analysis of the Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis as First-Line Therapy (AMPLIFY) Trial. Liu X; Johnson M; Mardekian J; Phatak H; Thompson J; Cohen AT J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26627879 [TBL] [Abstract][Full Text] [Related]
15. Shortened hospital length of stay and lower costs associated with rivaroxaban in patients with pulmonary embolism managed as observation status. Weeda ER; Peacock WF; Fermann GJ; Baugh CW; Wells PS; Ashton V; Crivera C; Wildgoose P; Schein JR; Coleman CI Int J Clin Pract; 2017 Jan; 71(1):. PubMed ID: 28097761 [TBL] [Abstract][Full Text] [Related]
16. An early evaluation of bleeding-related hospital readmissions among hospitalized patients with nonvalvular atrial fibrillation treated with direct oral anticoagulants. Deitelzweig S; Bruno A; Trocio J; Tate N; Gupta K; Lin J; Lingohr-Smith M Curr Med Res Opin; 2016; 32(3):573-82. PubMed ID: 26652179 [TBL] [Abstract][Full Text] [Related]
17. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism. Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990 [TBL] [Abstract][Full Text] [Related]
18. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients. Fung KP; Chan KH; Ng V; Tsui PT; You JHS Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571 [TBL] [Abstract][Full Text] [Related]
19. Comparison of hospital length of stay between hospitalized non-valvular atrial fibrillation patients treated with either apixaban or warfarin. Farr AM; Jing Y; Johnston S; Trocio J; Singhal S; Bruno A; Graham J Hosp Pract (1995); 2015; 43(3):172-9. PubMed ID: 26213178 [TBL] [Abstract][Full Text] [Related]
20. Initiation of direct oral anticoagulants versus warfarin for venous thromboembolism: impact on time to hospital discharge. Basto AN; Fewel NP; Vo K; Stock EM; Ta M J Thromb Thrombolysis; 2018 Jan; 45(1):51-55. PubMed ID: 29086244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]